Erythropoiesis after nonmyeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation

Transplantation

Volumn 74, Issue 12, 2002, Pages 1692-1696

  Baron, F ^a   Fillet, G ^a   Beguin, Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; ERYTHROPOIETIN; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TRANSFERRIN RECEPTOR;

ADULT; ALLOTRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROPOIESIS; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORMONE SYNTHESIS; HUMAN; MALE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; WHOLE BODY RADIATION;

EID: 0037184790     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200212270-00008     Document Type: Article

References (42)

1. Thomas ED, Blume KG. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 1999; 5: 341.
2. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385.
3. Barrett J, Childs R. The benefits of an alloresponse: Graft-versus-tumor. J Hematother Stem Cell Res 2000; 9: 347.
4. Morecki S, Slavin S. Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease. J Hematother Stem Cell Res 2000; 9: 355.
5. Baron F, Beguin Y. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion 2000; 40: 468-476.
6. Porter DL. The graft-versus-tumor potential of allogeneic cell therapy: An update on donor leukocyte infusions and nonmyeloablative allogeneic stem cell transplantation. J Hematother Stem Cell Res 2001; 10: 465.
7. Baron F, Beguin Y. Nonmyeloablative allogeneic hematopoietic stem cell transplantation. J Hematother Stem Cell Res. 2002; 11:243.
8. Baron F, Siquet J, Schaaf-Lafontaine N, et al. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation. Haematologica 2002; 87: 78.
9. McSweeney PA, Niederwieser D, Shizuru J, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390.
10. Weissinger F, Sandmaier BM, Maloney DG, et al. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001; 98: 3584.
11. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048.
12. McSweeney PA, Storb R. Mixed chimerism: Preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999; 5: 192.
13. Zaucha JM, Zellmer E, Georges G, et al. G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplant 2001; 7: 613.
14. Zaucha JM, Yu C, Zellmer E, et al. Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model. Biol Blood Marrow Transplant 2001; 7: 513.
15. Zaucha JA, Yu C, Lothrop CD Jr, et al. Severe canine hereditary hemolytic anemia treated by nonmyeloablative marrow transplantation. Biol Blood Marrow Transplant 2001; 7: 14.
16. Baron F, Baudoux E, Frère P, et al. Nonmyeloablative stem cell transplantation (NMSCT) with CD8-depleted or CD34-selected PBSC. J Hematother Stem Cell Res 2002;11:301.
17. Beguin Y. A risk-benefit assessment of epoetin in the management of anaemia associated with cancer. Drug Saf 1998; 19: 269.
18. Abedi MR, Backman L, Bostrom L, et al. Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 6: 121.
19. Schapira L, Antin JH, Ransil BJ, et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990; 76: 2354.
20. Beguin Y, Clemons GK, Oris R, et al. Circulating erythropoietin levels after bone marrow transplantation: Inappropriate response to anemia in allogeneic transplants. Blood 1991; 77: 868.
21. Bosi A, Vannucchi AM, Grossi A, et al. Inadequate erythropoietin production in allogeneic bone marrow transplant patients. Haematologica 1991; 76: 280.
22. Bosi A, Vannucchi AM, Grossi A, et al. Serum erythropoietin levels in patients undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1991; 7: 421.
23. Lazarus HM, Goodnough LT, Goldwasser E, et al. Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: Implications for erythropoietin therapy in this setting. Bone Marrow Transplant 1992; 10: 71.
24. Miller CB, Jones RJ, Zahurak ML, et al. Impaired erythropoietin response to anemia after bone marrow transplantation. Blood 1992; 80: 2677.
25. Beguin Y, Oris R, Fillet G. Dynamics of erythropoietic recovery following bone marrow transplantation: Role of marrow proliferative capacity and erythropoietin production in autologous versus allogeneic transplants. Bone Marrow Transplant 1993; 11: 285.
26. Davies SV, Fegan CD, Kendall R, et al. Serum erythropoietin during autologous bone marrow transplantation: Relationship to measures of erythroid activity. Clin Lab Haematol 1995; 17: 139.
27. Beguin Y, Baron F, Fillet G. Influence of marrow activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. Haematologica 1998; 83: 1076.
28. Ireland RM, Atkinson K, Concannon A, et al. Serum erythropoietin changes in autologous and allogeneic bone marrow transplant patients. Br J Haematol 1990; 76: 128.
29. Vannucchi AM, Grossi A, Bosi A, et al. Impaired erythropoietin production in mice treated with cyclosporin A. Blood 1991; 78: 1615.
30. Vannucchi AM, Grossi A, Bosi A, et al. Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line. Blood 1993; 82: 978.
31. Beguin Y, Clemons GK, Pootrakul P, et al. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81: 1067.
32. Locatelli F, Zecca M, Pedrazzoli P, et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: Effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 1994; 13: 403.
33. Link H, Boogaerts MA, Fauser AA, et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994; 84: 3327.
34. Baron F, Sautois B, Baudoux E, et al. Optimization of recombinant human erythropoietin (rHuEpo) after allogeneic hematopoietic stem cell transplantation (HSCT). Exp Hematol 2002;30:546.
35. Birgegard G, Wide L, Simonsson B. Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation. Br J Haematol 1989; 72: 462.
36. Beguin Y, Collignon J, Laurent C, et al. Spontaneous complete remission and recovery of donor haemopoiesis without GVHD after relapse and apparent marrow graft rejection in poor-prognosis myelodysplastic syndrome. Br J Haematol 1996; 94: 507.
37. Cazzola M, Guarnone R, Cerani P, et al. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 1998; 91: 2139.
38. Lezon C, Alippi RM, Barcelo AC, et al. Depression of stimulated erythropoietin production in mice with enhanced erythropoiesis. Haematologica 1995; 80: 491.
39. Piroso E, Erslev AJ, Flaharty KK, et al. Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am J Hematol 1991; 36: 105.
40. Naets JP, Wittek M. Effect of erythroid hyperplasia on utilization of erythropoietin. Nature 1965; 206: 726.
41. Pelot MR, Pearson DA, Swenson K, et al. Lymphohematopoietic graft-versus-host reactions can be induced without graft-versus-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133.
42. Hellwig-Burgel T, Rutkowski K, Metzen E, et al. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999; 94: 1561.